GlassScriptPhysician profile
Omar Shahbaz
NPI 1417226366
$4,182.29
in general payments reported to CMS, 2019-2025
34 companies · $948 in 2025
The $948 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $46.37 · 2021: $1,120 · 2022: $714 · 2023: $422 · 2024: $491 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834 · Education: $26.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.32 |
| Education | $26.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,154.86 | 2020-2025 | Skyrizi, Rinvoq |
| Madrigal Pharmaceuticals | $582.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $456.52 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $222.96 | 2023-2025 | Stelara, Simponi Aria, Simponi |
| Conmed Corporation | $217.31 | 2019 | |
| Axonics, INC. | $155.33 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $154.97 | 2019-2024 | Lokelma |
| Lucid Diagnostics INC. | $145.05 | 2023 | |
| Gilead Sciences, INC. | $120.68 | 2019-2025 | |
| Intuitive Surgical, INC. | $93.27 | 2022 | |
| Ardelyx, INC. | $86.89 | 2024-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $80.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $77.29 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $73.17 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $63.67 | 2023-2025 | Ocaliva |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $55.20 | 2021-2023 | |
| Edwards Lifesciences Corporation | $54.53 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Celltrion USA INC. | $54.03 | 2024-2025 | Vegzelma, Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $36.65 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $30.27 | 2025 | Iqirvo |
| Exact Sciences Corporation | $26.16 | 2025 | Cologuard Collection Kit |
| Chiesi USA, INC. | $25.16 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.74 | 2023 | Dupixent |
| Vivus LLC | $21.17 | 2025 | Pancreaze |
| Cleerly, INC. | $20.95 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Teva Pharmaceuticals USA, INC. | $20.62 | 2025 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $19.12 | 2019 | |
| Merck Sharp & Dohme LLC | $18.52 | 2022 | |
| Pfizer INC. | $17.62 | 2025 | |
| Lilly USA, LLC | $17.44 | 2025 | Mounjaro, Zepbound |
| Amgen INC. | $16.90 | 2019 | |
| Braintree Laboratories, INC. | $16.03 | 2024 | Sutab, Suflave |
| Endogastric Solutions, INC | $12.22 | 2023 | Esophyx |
| Olympus America INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Shahbaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.